Get started
Author

Sunitha Gn

Observed names: S. Gn, SUNITHA G.N, Sunitha GN
ORCID: 0000-0002-2696-5340
Observed ORCID: 0000-0002-2696-5340
OpenAlex ID: A5075207387
Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies
2017 · Darko Skegro, Cian Stutz, et al. · Journal of Biological Chemistry · 50
PDF
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
2023 · Barbara Rewerska, Lawrence D. Sher, et al. · Journal of Allergy and Clinical Immunology Global · 48
Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development
2019 · Romain Ollier, Paul Wassmann, et al. · mAbs · 22
Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
2022 · Sanjay R Mohan, Cristiana Costa Chase, et al. · Blood · 14
Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
2023 · Prashant Kapoor, Don A. Stevens, et al. · Blood · 12
Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
2023 · Dickran Kazandjian, Hang Quach, et al. · Blood · 7
ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma
2021 · Sammicheli Stefano, Camille Grandclement, et al. · Blood · 7
1094 Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis
2018 · G. Gudi, V.C. A, et al. · Journal of Investigative Dermatology · 4
PDF
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients
2026 · Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, et al. · Clinical Pharmacology & Therapeutics · 3
Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients
2025 · Vinu Menon, Beata Holkova, et al. · Cancer Research · 2
554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)
2025 · Andrew Garton, Vinu Menon, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
2025 · Andrew Garton, Vinu Menon, et al. · Cancer Research · 1
Preliminary pharmacokinetic results from a phase I study of GBR 1302 in patients with HER2 positive cancers
2018 · G. Gudi, V. Ca, et al. · Annals of Oncology · 1
ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection
2024 · Vinu Menon, Lida Pacaud, et al. · Blood
PDF
Abstract 2903: ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies
2022 · Stefano Sammicheli, Camille Grandclement, et al. · Cancer Research
15182 Population pharmacokinetic modeling and simulations for GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40, to support clinical development in patients with moderate to severe atopic dermatitis
2020 · Girish Gudi, C.A. Vinu, et al. · Journal of the American Academy of Dermatology
In vitro pharmacokinetic drug interaction study Of combination of antiretroviral and Antimalarial drugs
2018 · SUNITHA G.N, B.M.V SWAMY, et al. · International Journal of Pharma and Bio Sciences
Works count: 17
Citation count: 172
H-index: 7
I10-index: 5
Year
Topic
Type